Clinical Trial Update: GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease [Phase 2, Phase 3]

View source ↗

Summary

GRAVITAS-309 evaluated itacitinib with corticosteroids as initial therapy for chronic graft-versus-host disease; the Phase 2/3 trial was terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Corticosteroids (corticosteroids)
• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Graft-versus-host Disease | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2025-01-27